ATE302000T1 - Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen - Google Patents

Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen

Info

Publication number
ATE302000T1
ATE302000T1 AT01943711T AT01943711T ATE302000T1 AT E302000 T1 ATE302000 T1 AT E302000T1 AT 01943711 T AT01943711 T AT 01943711T AT 01943711 T AT01943711 T AT 01943711T AT E302000 T1 ATE302000 T1 AT E302000T1
Authority
AT
Austria
Prior art keywords
depression
treatment
pharmaceutical composition
composition containing
famotidine
Prior art date
Application number
AT01943711T
Other languages
English (en)
Inventor
Anna Racz
Peter Kovacs
Csilla Varga
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Application granted granted Critical
Publication of ATE302000T1 publication Critical patent/ATE302000T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
AT01943711T 2000-06-06 2001-06-06 Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen ATE302000T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0002154A HUP0002154A3 (en) 2000-06-06 2000-06-06 Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
PCT/HU2001/000065 WO2001093863A2 (en) 2000-06-06 2001-06-06 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression

Publications (1)

Publication Number Publication Date
ATE302000T1 true ATE302000T1 (de) 2005-09-15

Family

ID=89978380

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943711T ATE302000T1 (de) 2000-06-06 2001-06-06 Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen

Country Status (10)

Country Link
US (1) US20040010021A1 (de)
EP (1) EP1289520B1 (de)
JP (1) JP2003535133A (de)
AT (1) ATE302000T1 (de)
AU (1) AU2001266242A1 (de)
DE (1) DE60112750T2 (de)
DK (1) DK1289520T3 (de)
ES (1) ES2247137T3 (de)
HU (1) HUP0002154A3 (de)
WO (1) WO2001093863A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
US20150329540A1 (en) 2012-12-28 2015-11-19 Shin Nippon Biomedical Laboratories, Ltd. Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
WO2015002150A1 (ja) 2013-07-03 2015-01-08 株式会社新日本科学 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
IL311338A (en) * 2024-03-07 2025-10-01 Ariel Scient Innovations Ltd Using hyaluronic acid to treat mental disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460825A (en) * 1990-05-23 1995-10-24 Mcneil-Ppc, Inc. Taste mask coatings for preparing chewable pharmaceutical tablets
US5352688A (en) * 1991-02-14 1994-10-04 The Mount Sinai School Of Medicine Of The City University Of New York Methods for the treatment of bradyphrenia in parkinson's disease
WO1995001780A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-alginate combinations
WO1995001784A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-sucralfate-antiflatulent combinations

Also Published As

Publication number Publication date
HUP0002154A3 (en) 2002-06-28
EP1289520B1 (de) 2005-08-17
WO2001093863A2 (en) 2001-12-13
US20040010021A1 (en) 2004-01-15
WO2001093863A3 (en) 2002-05-02
JP2003535133A (ja) 2003-11-25
AU2001266242A1 (en) 2001-12-17
DE60112750T2 (de) 2006-06-08
HU0002154D0 (en) 2000-08-28
HUP0002154A2 (hu) 2002-04-29
DE60112750D1 (de) 2005-09-22
DK1289520T3 (da) 2005-10-17
EP1289520A2 (de) 2003-03-12
ES2247137T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60320095D1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE60225556D1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
ECSP045115A (es) INDOL-2-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
ATE506059T1 (de) Therapie zur behandlung der überaktiven blase
HRP20090058A2 (hr) Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
ATE369861T1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
DK1343472T3 (da) Thixotropisk næsespray
DE60112750D1 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
DE60108130D1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
MX2025002176A (es) Inhibidores de tyk2 y usos de los mismos
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
ATE259223T1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1289520

Country of ref document: EP

REN Ceased due to non-payment of the annual fee